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Natural and Nonnatural Vitamin Ds Compared
with the Protein-Bound Vitamin
Structures of the active vitamin D metabolite
1,25(OH)2D3 (A), the related synthetic agonist
LG190155 (B), and the 1,25(OH)2D3-VDR com-
plex (C). In (C), the VDR arginine residue
(Arg274) known to be mutated to a smaller
hydrophobic leucine residue in cases of vita-
min D-resistant rickets and the proximal
1-hydroxyl group (1-OH) of 1,25(OH)2D3 modi-
fied to compensate for this mutation are ex-
plicitly shown.
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vances in gene manipulation have allowed researchers
to conduct more elegant experiments to dissect these
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Control in the N-linked Glycoprotein
Biosynthesis Pathway processes at the molecular level, and ultimately lend
support to the hypotheses generated by Lennarz’s ear-
lier work. Marth and colleagues strived to disrupt the
key glycosyltransferase genes using homologous re-N-linked glycosylation is vital for the development and
combination in mouse, and in this way showed thatmaintenance of eukaryotic cells. The individual steps
deletion of these genes resulted in embryonic lethality;of this complex process are slowly being elucidated.
interestingly, the earlier in the pathway the gene is de-In this issue, the Imperiali group further dissects the
leted, the less progressive the embryonic development.mechanics of oligosaccharyl transferase using sub-
Specifically, in this study, Marth and coworkers demon-strate analogs.
strated that disrupting the gene that encodes for the
dolichol GlcNAc-1-phosphotransferase (see figure), theThe glycosylation of proteins requires a significant com-
enzyme inhibited by tunicamycin, blocks mouse devel-mitment of genetic and energetic resources by eukary-
opment at gastrulation, precisely as Lennarz had shownotic cells. Since this complex process was discovered,
earlier in sea urchins [2, 3]. By contrast, mouse embryosresearchers have been trying to uncover and understand
that were homozygous for a disrupted gene encodingthe various steps and molecular mechanisms of glyco-
the protein N-acetylglucosylaminyltransferase I, an en-sylation that nature accomplishes with apparent ease.
zyme that acts at a later stage in the glycosylation path-The critical importance of N-linked (or asparagine-
way for the synthesis of complex N-linked oligosaccha-linked) glycosylation to multicellular organization was
rides, progress through the initial developmental events,demonstrated several years ago by Lennarz, who treated
but stop abruptly at embryonic stage E9.5–E10.5 [4, 5].sea urchin embryos with tunicamycin to completely ab-
Intervening in the early steps in the dolichol lipid path-late N-linked glycosylation and observed the cessation
of embryonic development [1]. Since that time, ad- way for N-linked glycosylation by either chemical or
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Oligosaccharide Transfer to Peptide in the Endoplasmic Reticulum
GlcNAc-1-phosphotransferase catalyses the first step in dolichol lipid oligosaccharide assembly. This step is inhibited by tunicamycin,
preventing further N-linked glycosylation via a number of ER-resident glycosyltransferases that generate dolichol-P-P-GlcNAc2Man9Glc3 as
shown. The structure of the glycan is a molecular model based on the NMR structure (Petrescu et al.). The probable recognition elements
that are required for oligosaccharyl transferase (OT) are shown. (A), an extended structure that includes the terminal 1,2 glucose residue
(G1) and chitobiose core; (B), the Asn-Xaa-Ser/Thre motif. Following transfer, rearrangements of the peptide regions flanking the sequon
stabilize the structure, resulting in weaker interaction at the active site. Processing of the protein-linked oligosaccharide by -glucosidases
I and II leaves a terminal 1,3 glucose residue (G3) that forms part of the calnexin binding motif (C).
biological means therefore has dramatic consequences ing enzyme inhibitors that prevent monoglucosylated
glycans from interacting with calnexin to promote incor-for the cell. Some understanding of this effect has been
gained by elucidating the role of carbohydrate ligands rect protein folding in viral glycoproteins, which are gly-
cosylated using the host cell pathway, as a potentialin critical lectin-like chaperone-mediated protein folding
events in the endoplasmic reticulum (ER) [6]. Following treatment for many viral diseases, including hepatitis [7].
Key to eukaryotic N-linked glycosylation is the ribosomaltransfer of the glycan from the dolichol lipid donor to
the nascent protein, the glucose “cap” is sequentially complex, or translocon, that includes the oligosaccharyl
transferase (OT) enzyme that transfers the assembled do-removed from the now N-linked glycan by specific glu-
cosidases in the ER lumen to leave a single glucose nor oligosaccharide from dolichol in the ER membrane to
specific asparagine residues in the protein (see figure).residue and several “exposed” mannose sugars. This
glucose is a ligand recognized by calnexin to retain the Many of the structural and enzyme components of the
translocon show a remarkable degree of homology innascent protein in the ER and allow the protein folding
machinery, in particular, disulphide bond formation, to yeast and man, supporting the hypothesis that this pro-
cess developed during early evolution. However, littletake place. If the deglucosylated protein is folded suc-
cessfully, the glycan is further processed in the ER and structural information has been obtained for OT, and
while we wait for the crystal structure of this enzyme,Golgi to generate a mature glycoprotein. Another ER
resident enzyme, a glucosyltransferase, detects mis- much can be gleaned from careful analysis of the sub-
strate requirements of OT and by the use of site directedfolded proteins and directs calnexin to these proteins
to assist with correct folding by transferring a single inhibitors of enzyme activity [8]. One interesting biologi-
cal conundrum is how OT successfully negotiates prod-glucose residue to their glycan to be recognized by
calnexin. This cycle continues until the protein has either uct inhibition, since it must be able to accommodate
the oligosaccharide attached to both lipid (dolichol) andadopted its folded conformation or is removed from the
lumen and targeted to the lysosome for degradation. the nascent protein. The OT may appear to be unregu-
lated in many cells because the continuous rate of syn-These molecular events have been identified in several
eukaryotic species throughout the evolutionary hierar- thesis of the dolichol lipid precursor is not always
equaled by the rate at which the oligosaccharide ischy, suggesting that N-linked glycosylation may have
been conserved to ensure the integrity of protein folding. transferred to the protein. Excess dolichyl oligosaccha-
ride can be created when there are either insufficientConversely, researchers have exploited this idea by us-
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protein acceptors passing through the ER, or under cir- uct is released, the active site for transfer would now
be accessible for dolichyl oligosaccharide binding tocumstances where the N-glycosylation consensus se-
quence (Asn-X-Ser/Thre motif) is not glycosylated. Al- incoming peptide, ensuring a continuous and efficient
supply of N-linked glycosylated protein, as specified bythough this site is consistently glycosylated in many
individual proteins, the local protein environment may the protein sequence.
The Imperiali group also shows that the use of productdictate incomplete glycosylation. Currently, a clear un-
derstanding of this mechanism is lacking, but in either mimics of OT reactants allows further definition of the
mechanism of action of this enigmatic enzyme and dem-case, the resultant dolichyl oligosaccharide is cleaved
and free oligosaccharide is generated. This oligosac- onstrates the exquisite means that enzymes use to con-
trol biologically significant processes in eukaryotic cells.charide is eventually cleared from the lumen of the ER
to the lysosome, after limited digestion with cytosolic
mannosidases [9]. Terry D. Butters
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Combinatorial Glycosylation
of Glycopeptide Antibiotics including methicillin-resistant Staphylococcus aureus
(MRSA) [2, 3]. With the emergence of vancomycin-resis-
tant enterococci (VRE) and S. aureus (VRSA), the devel-
opment of new derivatives of vancomycin [4] and the
The glycosyltransferases GtfE and GtfD from the van- development of other antibiotics with new modes of
comycin producer Amycolatopsis orientalis have pro- action (e.g., daptomycin [5]) are important for the treat-
miscuous substrate and NDP-sugar specificities. They ment of life-threatening gram-positive infections.
have been used to generate novel glycopeptide antibi- Like vancomycin, chloroeremomycin is produced by
otics containing the heptapeptide scaffolds of vanco- a strain of A. orientalis [6]. Chloroeremomycin differs
mycin and teichoplanin [1]. from vancomycin in its pattern of glycosylation. Vanco-
mycin has the disaccacharide D-glucose-L-vancosamine
The glycopeptide antibiotics vancomycin and teico- attached to the phenolic group of hydroxyphenylglycine
planin are secondary metabolites produced by soil acti- at amino acid 4 of the heptapeptide. Chloeremomycin
has the disaccharide D-glucose-L-4-epi-vancosaminenomycetes, A. orientalis and Actinoplanes teichomyceti-
